Randomized phase ii study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer

Journal of Thoracic Oncology

Volumn 8, Issue 3, 2013, Pages 338-345

  Bonomi, Philip D ^a   MacE, Joseph ^b   Mandanas, Romeo A ^c   Min, Myo ^d   Olsen, Mark ^e   Youssoufian, Hagop ^f   Katz, Terry L ^f   Sheth, Grishma ^g   Lee, Hyun Jung ^h  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b Gulfcoast Oncology Associates   (United States)

^c Integris Cancer Institute of Oklahoma   (United States)

^d Maryland Hematol Oncol Associates   (United States)

^e Cancer Care Associates   (United States)

^f ImClone Systems   (United States)

^g I3 Statprobe ^*  (United States)

^h ELI LILLY AND COMPANY   (United States)

Author keywords

Bevacizumab; Carboplatin; Cetuximab; Non small cell lung cancer; Paclitaxel

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CONTROLLED STUDY; DERMATITIS; FATIGUE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84874106904     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318282ded5     Document Type: Article

References (19)

1. Earle CC, Evans WK. Management Issues for Stage IV Non-Small Cell Lung Cancer. Cancer Control 1997;4: 307-316.
2. Non-small Cell Lung Cancer Collaborative Group (NSCLCCG). Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311: 899-909.
3. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355: 2542-2550.
4. Rosell R, Robinet G, Szczesna A, et al. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol 2008;19: 362-369.
5. Butts CA, Bodkin D, Middleman EL, et al. Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J Clin Oncol 2007;25: 5777-5784.
6. Thienelt CD, Bunn PA Jr, Hanna N, et al. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol 2005;23: 8786-8793.
7. Smith IE, O'Brien ME, Talbot DC, et al. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 2001;19: 1336-1343.
8. von Plessen C, Bergman B, Andresen O, et al. Palliative chemotherapy beyond three courses conveys no survival or consistent qualityof- life benefits in advanced non-small-cell lung cancer. Br J Cancer 2006;95: 966-973.
9. Wildiers H, Guetens G, De Boeck G, et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 2003;88: 1979-1986.
10. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004;64: 3731-3736.
11. Pirker R, Pereira JR, Szczesna A, et al.; FLEX Study Team. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009;373: 1525-1531.
12. Lynch TJ, Patel T, Dreisbach L, et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010;28: 911-917.
13. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92: 205-216.
14. Cella DF, Bonomi AE, Lloyd SR, Tulsky DS, Kaplan E, Bonomi P. Reliability and validity of the Functional Assessment of Cancer Therapy- Lung (FACT-L) quality of life instrument. Lung Cancer 1995;12: 199-220.
15. Cella D. Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System. Evanston Illinois: Center on Outcomes, Research and Education (CORE). Evanston Northwestern Healthcare and Northwestern University, Version 4, 1997.
16. Lilenbaum RC, Herndon JE 2nd, List MA, et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol 2005;23: 190-196.
17. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27: 1227-1234.
18. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009;360: 563-572.
19. Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009;27: 672-680.